Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)

NCT06631287 is registered in ClinicalTrials.gov with Wes Ely as lead sponsor.

NCT NCT06631287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06631287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)
Lead sponsor
Wes Ely
Phase
Phase 3
Overall status
Recruiting
Start date
October 21, 2024
Completion date
July 1, 2027
Enrollment
550 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections, covid-19, long covid, sars-cov-2 infection